REGN logo

REGN EBITDA

Annual EBITDA:

$5.32B+$624.70M(+13.31%)
December 31, 2024

Summary

  • As of today, REGN annual EBITDA is $5.32 billion, with the most recent change of +$624.70 million (+13.31%) on December 31, 2024.
  • During the last 3 years, REGN annual EBITDA has fallen by -$4.35 billion (-45.00%).
  • REGN annual EBITDA is now -45.00% below its all-time high of $9.67 billion, reached on December 31, 2021.

Performance

REGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

Quarterly EBITDA:

$1.25B+$22.00M(+1.80%)
September 30, 2025

Summary

  • As of today, REGN quarterly EBITDA is $1.25 billion, with the most recent change of +$22.00 million (+1.80%) on September 30, 2025.
  • Over the past year, REGN quarterly EBITDA has dropped by -$110.80 million (-8.16%).
  • REGN quarterly EBITDA is now -63.53% below its all-time high of $3.42 billion, reached on June 30, 2021.

Performance

REGN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

TTM EBITDA:

$4.36B-$110.80M(-2.48%)
September 30, 2025

Summary

  • As of today, REGN TTM EBITDA is $4.36 billion, with the most recent change of -$110.80 million (-2.48%) on September 30, 2025.
  • Over the past year, REGN TTM EBITDA has dropped by -$252.80 million (-5.49%).
  • REGN TTM EBITDA is now -53.74% below its all-time high of $9.41 billion, reached on March 31, 2022.

Performance

REGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherREGNincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

REGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+13.3%-8.2%-5.5%
3Y3 Years-45.0%-5.3%-35.7%
5Y5 Years+99.2%+12.1%+31.4%

REGN EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-45.0%+13.3%-11.9%+70.6%-35.7%at low
5Y5-Year-45.0%+99.2%-63.5%+70.6%-53.7%+31.4%
All-TimeAll-Time-45.0%+3218.6%-63.5%+2478.2%-53.7%+2601.8%

REGN EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$1.25B(+1.8%)
$4.36B(-2.5%)
Jun 2025
-
$1.22B(+67.5%)
$4.47B(+0.2%)
Mar 2025
-
$730.90M(-36.6%)
$4.46B(-3.1%)
Dec 2024
$5.32B(+13.3%)
$1.15B(-15.1%)
$4.60B(-0.2%)
Sep 2024
-
$1.36B(+11.8%)
$4.61B(+0.9%)
Jun 2024
-
$1.21B(+39.1%)
$4.57B(+2.1%)
Mar 2024
-
$872.60M(-25.0%)
$4.47B(-4.9%)
Dec 2023
$4.69B(-10.8%)
$1.16B(-11.6%)
$4.70B(-5.1%)
Sep 2023
-
$1.32B(+17.6%)
$4.95B(+0.0%)
Jun 2023
-
$1.12B(+1.6%)
$4.95B(-5.0%)
Mar 2023
-
$1.10B(-22.1%)
$5.22B(-4.7%)
Dec 2022
$5.26B(-45.6%)
$1.42B(+7.5%)
$5.47B(-19.2%)
Sep 2022
-
$1.32B(-4.7%)
$6.77B(-8.2%)
Jun 2022
-
$1.38B(+1.5%)
$7.38B(-21.6%)
Mar 2022
-
$1.36B(-49.9%)
$9.41B(+2.0%)
Dec 2021
$9.67B(+135.7%)
$2.71B(+41.3%)
$9.23B(+19.2%)
Sep 2021
-
$1.92B(-43.8%)
$7.75B(+11.6%)
Jun 2021
-
$3.42B(+189.7%)
$6.94B(+63.8%)
Mar 2021
-
$1.18B(-4.0%)
$4.24B(+11.1%)
Dec 2020
$4.10B(+53.7%)
$1.23B(+10.5%)
$3.81B(+15.0%)
Sep 2020
-
$1.11B(+55.5%)
$3.31B(+10.7%)
Jun 2020
-
$715.20M(-5.4%)
$2.99B(+13.1%)
Mar 2020
-
$756.20M(+3.6%)
$2.65B(+9.3%)
Dec 2019
$2.67B(-2.2%)
$730.00M(-7.8%)
$2.42B(-1.3%)
Sep 2019
-
$791.40M(+115.2%)
$2.45B(+5.6%)
Jun 2019
-
$367.70M(-30.8%)
$2.32B(-11.0%)
Mar 2019
-
$531.00M(-30.2%)
$2.61B(-2.7%)
Dec 2018
$2.73B(+21.4%)
$760.86M(+14.9%)
$2.68B(+7.5%)
Sep 2018
-
$662.36M(+1.0%)
$2.50B(+2.7%)
Jun 2018
-
$655.83M(+8.7%)
$2.43B(+3.0%)
Mar 2018
-
$603.59M(+5.3%)
$2.36B(+6.1%)
Dec 2017
$2.25B(+56.0%)
$573.32M(-4.1%)
$2.23B(+9.7%)
Sep 2017
-
$597.64M(+2.1%)
$2.03B(+11.4%)
Jun 2017
-
$585.44M(+24.9%)
$1.82B(+17.3%)
Mar 2017
-
$468.66M(+24.7%)
$1.55B(+8.1%)
Dec 2016
$1.44B(+9.7%)
$375.90M(-3.8%)
$1.44B(+9.3%)
Sep 2016
-
$390.64M(+23.4%)
$1.31B(-1.7%)
Jun 2016
-
$316.66M(-10.1%)
$1.34B(-3.2%)
Mar 2016
-
$352.29M(+38.7%)
$1.38B(+4.0%)
Dec 2015
$1.31B(+54.4%)
$253.99M(-38.5%)
$1.33B(-0.6%)
Sep 2015
-
$413.10M(+14.7%)
$1.33B(+19.4%)
Jun 2015
-
$360.16M(+20.2%)
$1.12B(+12.6%)
Mar 2015
-
$299.58M(+14.6%)
$993.23M(+11.5%)
Dec 2014
$851.29M(+8.6%)
$261.50M(+32.9%)
$891.12M(+4.5%)
Sep 2014
-
$196.72M(-16.4%)
$852.98M(-5.6%)
Jun 2014
-
$235.42M(+19.2%)
$903.86M(+8.1%)
Mar 2014
-
$197.47M(-11.6%)
$836.24M(+4.4%)
Dec 2013
$784.02M(+57.9%)
$223.37M(-9.8%)
$801.23M(+9.2%)
Sep 2013
-
$247.60M(+47.6%)
$733.41M(+5.0%)
Jun 2013
-
$167.81M(+3.3%)
$698.70M(+11.0%)
Mar 2013
-
$162.46M(+4.4%)
$629.29M(+26.5%)
Dec 2012
$496.67M(+391.3%)
$155.55M(-26.9%)
$497.45M(+63.4%)
Sep 2012
-
$212.89M(+116.4%)
$304.43M(+636.1%)
Jun 2012
-
$98.39M(+221.4%)
$41.35M(+137.8%)
Mar 2012
-
$30.62M(+181.7%)
-$109.46M(+37.1%)
Dec 2011
-$170.53M(-125.4%)
-$37.48M(+25.3%)
-$174.08M(-21.5%)
Sep 2011
-
-$50.18M(+4.3%)
-$143.29M(-19.1%)
Jun 2011
-
-$52.42M(-54.2%)
-$120.31M(-38.1%)
Mar 2011
-
-$34.00M(-408.2%)
-$87.09M(-12.3%)
Dec 2010
-$75.66M(-36.7%)
-$6.69M(+75.4%)
-$77.57M(+26.4%)
Sep 2010
-
-$27.20M(-41.7%)
-$105.35M(-38.9%)
Jun 2010
-
-$19.20M(+21.6%)
-$75.85M(-8.5%)
Mar 2010
-
-$24.48M(+29.0%)
-$69.92M(-16.8%)
Dec 2009
-$55.37M(+4.1%)
-$34.47M(-1599.5%)
-$59.86M(-4.4%)
Sep 2009
-
$2.30M(+117.3%)
-$57.36M(+25.3%)
Jun 2009
-
-$13.27M(+8.0%)
-$76.81M(+4.0%)
Mar 2009
-
-$14.41M(+54.9%)
-$79.99M(-1.8%)
Dec 2008
-$57.74M(+29.6%)
-$31.97M(-86.4%)
-$78.54M(-42.3%)
Sep 2008
-
-$17.16M(-4.3%)
-$55.20M(+25.3%)
Jun 2008
-
-$16.45M(-26.9%)
-$73.86M(+13.3%)
Mar 2008
-
-$12.96M(-50.1%)
-$85.14M(+17.3%)
DateAnnualQuarterlyTTM
Dec 2007
-$82.07M(+11.8%)
-$8.63M(+75.9%)
-$102.97M(+17.2%)
Sep 2007
-
-$35.81M(-29.1%)
-$124.41M(-9.9%)
Jun 2007
-
-$27.73M(+9.9%)
-$113.19M(-7.0%)
Mar 2007
-
-$30.79M(-2.4%)
-$105.82M(-14.1%)
Dec 2006
-$93.06M(-166.5%)
-$30.08M(-22.3%)
-$92.72M(-7.7%)
Sep 2006
-
-$24.59M(-20.8%)
-$86.07M(+6.4%)
Jun 2006
-
-$20.36M(-15.1%)
-$91.93M(+8.0%)
Mar 2006
-
-$17.69M(+24.5%)
-$99.91M(+6.4%)
Dec 2005
$139.93M(+566.1%)
-$23.43M(+23.0%)
-$106.70M(-41.6%)
Sep 2005
-
-$30.45M(-7.5%)
-$75.38M(-49.2%)
Jun 2005
-
-$28.34M(-15.7%)
-$50.53M(-62.8%)
Mar 2005
-
-$24.48M(-410.3%)
-$31.04M(-247.8%)
Dec 2004
$21.01M(+124.1%)
$7.89M(+240.8%)
$21.01M(+7070.0%)
Sep 2004
-
-$5.60M(+36.7%)
$293.00K(+101.8%)
Jun 2004
-
-$8.85M(-132.1%)
-$16.15M(+48.8%)
Mar 2004
-
$27.57M(+314.9%)
-$31.56M(+63.0%)
Dec 2003
-$87.05M(+23.3%)
-$12.82M(+41.8%)
-$85.22M(+18.8%)
Sep 2003
-
-$22.05M(+9.1%)
-$105.00M(+7.9%)
Jun 2003
-
-$24.25M(+7.0%)
-$113.96M(+3.0%)
Mar 2003
-
-$26.09M(+20.0%)
-$117.43M(-2.5%)
Dec 2002
-$113.50M(-42.6%)
-$32.61M(-5.2%)
-$114.53M(-4.4%)
Sep 2002
-
-$31.01M(-11.8%)
-$109.70M(-9.2%)
Jun 2002
-
-$27.72M(-19.6%)
-$100.47M(-12.4%)
Mar 2002
-
-$23.18M(+16.5%)
-$89.41M(-12.3%)
Dec 2001
-$79.61M(-281.7%)
-$27.78M(-27.6%)
-$79.61M(-35.0%)
Sep 2001
-
-$21.77M(-30.7%)
-$58.98M(-30.4%)
Jun 2001
-
-$16.67M(-24.5%)
-$45.23M(-43.6%)
Mar 2001
-
-$13.38M(-86.9%)
-$31.50M(-29.1%)
Dec 2000
-$20.86M(-2.2%)
-$7.16M(+10.8%)
-$24.40M(-30.8%)
Sep 2000
-
-$8.03M(-174.0%)
-$18.66M(-27.9%)
Jun 2000
-
-$2.93M(+53.4%)
-$14.58M(+21.5%)
Mar 2000
-
-$6.28M(-343.4%)
-$18.57M(+6.8%)
Dec 1999
-$20.40M(-114.7%)
-$1.42M(+64.1%)
-$19.93M(+27.9%)
Sep 1999
-
-$3.95M(+42.9%)
-$27.65M(-13.7%)
Jun 1999
-
-$6.92M(+9.4%)
-$24.31M(-66.8%)
Mar 1999
-
-$7.64M(+16.3%)
-$14.58M(-49.2%)
Dec 1998
-$9.50M(-2.2%)
-$9.14M(-1392.8%)
-$9.77M(-115.4%)
Sep 1998
-
-$612.00K(-121.8%)
-$4.54M(-12.7%)
Jun 1998
-
$2.81M(+199.1%)
-$4.03M(+56.9%)
Mar 1998
-
-$2.84M(+27.2%)
-$9.34M(+0.6%)
Dec 1997
-$9.30M(+17.0%)
-$3.90M(-3800.0%)
-$9.40M(-11.9%)
Sep 1997
-
-$100.00K(+96.0%)
-$8.40M(+25.0%)
Jun 1997
-
-$2.50M(+13.8%)
-$11.20M(-2.8%)
Mar 1997
-
-$2.90M(0.0%)
-$10.90M(+2.7%)
Dec 1996
-$11.20M(-558.8%)
-$2.90M(0.0%)
-$11.20M(-15.5%)
Sep 1996
-
-$2.90M(-31.8%)
-$9.70M(-27.6%)
Jun 1996
-
-$2.20M(+31.3%)
-$7.60M(-46.2%)
Mar 1996
-
-$3.20M(-128.6%)
-$5.20M(-108.0%)
Dec 1995
-$1.70M(+93.2%)
-$1.40M(-75.0%)
-$2.50M(+50.0%)
Sep 1995
-
-$800.00K(-500.0%)
-$5.00M(+26.5%)
Jun 1995
-
$200.00K(+140.0%)
-$6.80M(+57.5%)
Mar 1995
-
-$500.00K(+87.2%)
-$16.00M(+36.0%)
Dec 1994
-$25.00M(+30.0%)
-$3.90M(-50.0%)
-$25.00M(+20.4%)
Sep 1994
-
-$2.60M(+71.1%)
-$31.40M(+15.8%)
Jun 1994
-
-$9.00M(+5.3%)
-$37.30M(+0.3%)
Mar 1994
-
-$9.50M(+7.8%)
-$37.40M(-2.7%)
Dec 1993
-$35.70M(-119.0%)
-$10.30M(-21.2%)
-$36.40M(-15.2%)
Sep 1993
-
-$8.50M(+6.6%)
-$31.60M(-12.1%)
Jun 1993
-
-$9.10M(-7.1%)
-$28.20M(-27.6%)
Mar 1993
-
-$8.50M(-54.5%)
-$22.10M(-34.8%)
Dec 1992
-$16.30M(-85.2%)
-$5.50M(-7.8%)
-$16.40M(-14.7%)
Sep 1992
-
-$5.10M(-70.0%)
-$14.30M(-24.3%)
Jun 1992
-
-$3.00M(-7.1%)
-$11.50M(-11.7%)
Mar 1992
-
-$2.80M(+17.6%)
-$10.30M(-87.3%)
Dec 1991
-$8.80M(-193.3%)
-$3.40M(-47.8%)
-$5.50M(+39.6%)
Sep 1991
-
-$2.30M(-27.8%)
-$9.10M(-65.5%)
Jun 1991
-
-$1.80M(-190.0%)
-$5.50M(-120.0%)
Mar 1991
-
$2.00M(+128.6%)
-$2.50M(+24.2%)
Dec 1990
-$3.00M
-$7.00M(-638.5%)
-$3.30M(-189.2%)
Sep 1990
-
$1.30M(+8.3%)
$3.70M(+54.2%)
Jun 1990
-
$1.20M(0.0%)
$2.40M(+100.0%)
Mar 1990
-
$1.20M
$1.20M

FAQ

  • What is Regeneron Pharmaceuticals, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for Regeneron Pharmaceuticals, Inc.?
  • What is Regeneron Pharmaceuticals, Inc. annual EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Regeneron Pharmaceuticals, Inc.?
  • What is Regeneron Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
  • What is Regeneron Pharmaceuticals, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for Regeneron Pharmaceuticals, Inc.?
  • What is Regeneron Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

What is Regeneron Pharmaceuticals, Inc. annual EBITDA?

The current annual EBITDA of REGN is $5.32B

What is the all-time high annual EBITDA for Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. all-time high annual EBITDA is $9.67B

What is Regeneron Pharmaceuticals, Inc. annual EBITDA year-on-year change?

Over the past year, REGN annual EBITDA has changed by +$624.70M (+13.31%)

What is Regeneron Pharmaceuticals, Inc. quarterly EBITDA?

The current quarterly EBITDA of REGN is $1.25B

What is the all-time high quarterly EBITDA for Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. all-time high quarterly EBITDA is $3.42B

What is Regeneron Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?

Over the past year, REGN quarterly EBITDA has changed by -$110.80M (-8.16%)

What is Regeneron Pharmaceuticals, Inc. TTM EBITDA?

The current TTM EBITDA of REGN is $4.36B

What is the all-time high TTM EBITDA for Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc. all-time high TTM EBITDA is $9.41B

What is Regeneron Pharmaceuticals, Inc. TTM EBITDA year-on-year change?

Over the past year, REGN TTM EBITDA has changed by -$252.80M (-5.49%)
On this page